Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat. 2011 Jan 1;125(2):431-9.
Anto JM, Sunyer J, Basagana X, Garcia‐Esteban R, Cerveri I, de Marco R, Heinrich J, Janson C, Jarvis D, Kogevinas M, Kuenzli N, Leynaert B, Svanes C, Wjst M, Gislason T, Burney P. Risk factors of new-onset asthma in adults: a population-based international cohort study. Allergy. 2010 Aug;65(8):1021-30. doi: 10.1111/j.1398-9995.2009.02301.x
Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, Walker M, Geyer CE. Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009 Oct 1;117(3):577-89. doi: 10.1007/s10549-009-0310-8
Philpot E, Prillaman B, Wu W, Toler W. Correlation of patient-rated nasal congestion with peak nasal inspiratory flow assessments in three allergic rhinitis studies of fluticasone furoate nasal spray. Poster presented at the XXVIII EAACI Congress of the European Academy of Allergy and Clinical Immunology; June 2009. Warszawa, Poland. [abstract] Allergy. 2009; 64(S90):37-8.
Sunyer J, Pekkanen J, Garcia-Esteban R, Svanes C, Kunzli N, Janson C, de Marco R, Anto JM, Burney P. Asthma score: predictive ability and risk factors. Allergy. 2007 Feb;62(2):142-8. doi: 10.1111/j.1398-9995.2006.01184.x